{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T15:49:01Z","timestamp":1709308141583},"reference-count":16,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.vaccine.2007.10.002","type":"journal-article","created":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T12:20:25Z","timestamp":1194351625000},"page":"8405-8409","source":"Crossref","is-referenced-by-count":7,"title":["A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): A randomized simulated post-exposure study in healthy volunteers"],"prefix":"10.1016","volume":"25","author":[{"given":"Bangalore Jayakrishnappa","family":"Mahendra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shampur Narayan","family":"Madhusudana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doddabele Hanumanthaiah","family":"Ashwathnarayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gadey","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soma Subhra","family":"datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mysore Kalappa","family":"Sudarshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonibeedu Manjunatah","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kader","family":"Muhamuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangaboraiah","family":"Bilagumba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjula","family":"Shamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.10.002_bib1","unstructured":"World Health Organization. World survey of rabies no. 35 for the year 1999. WHO\/CDS\/CSR\/EPH\/2002.10. Geneva."},{"issue":"1","key":"10.1016\/j.vaccine.2007.10.002_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","article-title":"Assessing burden of human rabies in India: results of a national multi-center epidemiological survey","volume":"11","author":"Sudarshan","year":"2007","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2007.10.002_bib3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2460\/javma.2005.227.1912","article-title":"Rabies surveillance in the USA during 2004","volume":"227","author":"Krebs","year":"2005","journal-title":"J Am Vet Assoc"},{"key":"10.1016\/j.vaccine.2007.10.002_bib4","unstructured":"World Health Organization. WHO expert consultation on rabies. First report. WHO Tech Rep Ser 931. Geneva: WHO; 2005."},{"issue":"2","key":"10.1016\/j.vaccine.2007.10.002_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03160186","article-title":"Absence of myelin basic protein in an improved purified duck embryo vaccine","volume":"4","author":"Gluck","year":"1986","journal-title":"Neurochem Pathol"},{"key":"10.1016\/j.vaccine.2007.10.002_bib6","first-page":"1779G","article-title":"A highly efficient, highly purified duck embryo rabies vaccine","volume":"115","author":"Wegmann","year":"1985","journal-title":"Schweiz Med Wochenchr"},{"issue":"5","key":"10.1016\/j.vaccine.2007.10.002_bib7","first-page":"375","article-title":"Elimination of human rabies in a canine endemic province in Thailand: five year programme","volume":"81","author":"Kamoltham","year":"2003","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2007.10.002_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1708-8305.1999.tb00525.x","article-title":"Economic issues in post exposure rabies treatment","volume":"6","author":"Wild","year":"1999","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2007.10.002_bib9","series-title":"Laboratory techniques in rabies","first-page":"253","article-title":"Purified duck embryo vaccine for humans","author":"Gluck","year":"1996"},{"issue":"3","key":"10.1016\/j.vaccine.2007.10.002_bib10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/clinids\/20.3.646","article-title":"Immunogenicity of purified duck embryo vaccine (Lyssavac-N) with use of the WHO-approved intradermal post-exposure regimen","volume":"20","author":"Khawplod","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2007.10.002_bib11","unstructured":"World Health Organization. WHO expert committee on rabies. 8th Report. WHO Tech Rep Ser 824. Geneva: WHO; 1992."},{"key":"10.1016\/j.vaccine.2007.10.002_bib12","series-title":"Laboratory techniques in rabies","first-page":"181","article-title":"A rapid fluorescent focus inhibition test (RFFIT) for determining rabies-neutralizing antibody","author":"Smith","year":"1996"},{"issue":"5","key":"10.1016\/j.vaccine.2007.10.002_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4161\/hv.1.5.2110","article-title":"Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines: results of a meta-analysis","volume":"1","author":"Sudarshan","year":"2005","journal-title":"Hum Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2007.10.002_bib14","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo Cell rabies vaccine","volume":"23","author":"Beran","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.10.002_bib15","series-title":"Laboratory techniques in rabies","first-page":"271","article-title":"Cell culture vaccines for human use: general considerations","author":"Nicholson","year":"1996"},{"key":"10.1016\/j.vaccine.2007.10.002_bib16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(84)92286-4","article-title":"A new highly immunogenic duck embryo rabies vaccine","volume":"I","author":"Gluck","year":"1984","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07011413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07011413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T16:40:54Z","timestamp":1684082454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07011413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":16,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0264410X07011413"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.10.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}